FCR holds up to the test of time: CLL8 follow-Up

Abstract

In this issue of Blood, Fischer et al present long-term follow up of the chronic lymphocytic leukemia (CLL)8 study, which established fludarabine, cyclophosphamide, and rituximab (FCR) as the gold standard for initial therapy of fit patients with CLL.